Goodfellow says the tie-up is a significant endorsement of their ImmunoBody platform – the underlying technology behind both SCIB1 and SCIB2 - which helps to prime a patient’s immune system to recognise and kill specific cancer cells.
Thu, 14 Dec 2017 13:21:00
“We are delighted to announce this partnership with Cancer Research UK, which is a significant endorsement for our ImmunoBody technology”
Thu, 14 Dec 2017 11:06:00
Executive chairman John Chiplin said new CEO Dr Cliff Holloway's extensive experience and accomplishments speak volumes
Tue, 10 Oct 2017 08:24:00
Sign up to our newsletter to stay up to date with Scancell